Overview

• Biopharmaceutical firm's fiscal Q3 net loss widened to $18.9 mln

• R&D expenses increased due to PALISADE Program for social anxiety disorder

Outlook

• VistaGen implements cash preservation initiatives ahead of clinical milestones

Result Drivers

• R&D EXPENSES - Increased R&D expenses due to higher research, development, and contract manufacturing costs for the PALISADE Program

• CASH PRESERVATION - Implemented cash preservation initiatives to maintain strategic flexibility as clinical milestones approach

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $1.00, about 74.7% above its February 11 closing price of $0.57

Press Release: ID:nBw3NV4Yxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)